The mode of action (MOA) approach reveals interactive effects of environmental pharmaceuticals on Mytilus galloprovincialis

Aquatic Toxicology

Volumn 140-141, Issue , 2013, Pages 249-256

  Franzellitti, Silvia ^a   Buratti, Sara ^a   Valbonesi, Paola ^a   Fabbri, Elena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 HT1 receptor; ABCB mRNA expression; CAMP signaling; Fluoxetine; Mytilus galloprovincialis; Propranolol

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRUG RESIDUE; FLUOXETINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROPRANOLOL; SEROTONIN; SEROTONIN 1 RECEPTOR;

DRUG; ECOTOXICOLOGY; ENVIRONMENTAL RISK; GENE EXPRESSION; MOLLUSC; POLLUTION EFFECT; RISK ASSESSMENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXOCRINE GLAND; GENE EXPRESSION; GONAD; MYTILUS GALLOPROVINCIALIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SEROTONIN UPTAKE; SIGNAL TRANSDUCTION;

5-HT(1) RECEPTOR; ABCB MRNA EXPRESSION; CAMP SIGNALING; FLUOXETINE; MYTILUS GALLOPROVINCIALIS; PROPRANOLOL;

AMPHIBIAN PROTEINS; ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME ACTIVATION; FLUOXETINE; GENE EXPRESSION REGULATION; MYTILUS; PROPRANOLOL; WATER POLLUTANTS, CHEMICAL;

EID: 84880027136     PISSN: 0166445X     EISSN: 18791514     Source Type: Journal    
DOI: 10.1016/j.aquatox.2013.06.005     Document Type: Article

References (60)

1. Alexander B.S., Wood M.D. Stereoselective blockade of central [3H]5-hydroxytryptamine binding to multiple sites (5-HT1A, 5-HT1B and 5-HT1C) by mianserin and propranolol. Journal of Pharmacy and Pharmacology 1987, 39:664-666.
2. Ankley G.T., Brooks B.W., Huggett D.B., Sumpter J.P. Repeating history: pharmaceuticals in the environment. Environmental Science & Technology 2007, 41:8211-8217.
3. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Science of the Total Environment 2004, 333:167-184.
4. Banni M., Negri A., Mignone F., Boussetta H., Viarengo A., Dondero F. Gene expression rhythms in the mussel Mytilus galloprovincialis (Lam.) across an annual cycle. PLoS ONE 2011, 6:e18904.
5. Bard S.M. Multixenobiotic resistance as a cellular defence mechanism in aquatic organisms. Aquatic Toxicology 2000, 48:357-389.
6. Boxall A., Long C. Veterinary medicines and the environment. Environmental Toxicology and Chemistry 2005, 24:759-760.
7. Bringolf R.B., Heltsley R.M., Newton T.J., Eads C.B., Fraley S.J., Shea D., Cope W.G. Environmental occurrence and reproductive effects of the pharmaceutical fluoxetine in native freshwater mussels. Environmental Toxicology and Chemistry 2010, 6:1311-1318.
8. Brooks B.W., Foran C.M., Richards S.M., Weston J., Turner P.K., Stanley J.K., Solomon K.R., Slattery M., La Point T.W. Aquatic ecotoxicology of fluoxetine. Toxicology Letter 2003, 142:169-183.
9. Canesi L., Negri A., Barmo C., Banni M., Gallo G., Viarengo A., Dondero F. The organophosphate chlorpyrifos interferes with the responses to 17β-estradiol in the digestive gland of the marine mussel Mytilus galloprovincialis. PLoS ONE 2011, 6:e19803.
10. Christen V., Hickmann S., Rechenberg B., Fent K. Highly active human pharmaceuticals in aquatic systems: a concept for their identification based on their mode of action. Aquatic Toxicology 2010, 96:167-181.
11. Ciocan C.M., Cubero-Leon E., Minier C., Rotchell J.M. Identification of reproduction-specific genes associated with maturation and estrogen exposure in a marine bivalve Mytilus edulis. PLoS ONE 2011, 6:e22326.
12. Cleuvers M. Initial risk assessment for three beta-blockers found in the aquatic environment. Chemosphere 2005, 59:199-205.
13. Cubero-Leon E., Ciocan C.M., Hill E.M., Osada M., Kishida M., Itoh N., Kondo R., Minier C., Rotchell J.M. Estrogens disrupt serotonin receptor and cyclooxygenase mRNA expression in the gonads of mussels (Mytilus edulis). Aquatic Toxicology 2010, 98:178-187.
14. Cubero-Leon E., Ciocan C.M., Minier C., Rotchell J.M. Reference gene selection for qPCR in mussel, Mytilus edulis, during gametogenesis and exogenous estrogen exposure. Environmental Science and Pollution Research International 2012, 19:2728-2733.
15. De Vane C.L. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cellular and Molecular Neurobiology 1999, 19:443-466.
16. Dondero F., Piacentini L., Banni M., Rebelo M., Burlando B., Viarengo A. Quantitative PCR analysis of two molluscan metallothionein genes unveils differential expression and regulation. Gene 2005, 345:259-270.
17. [ECETOC] European Centre for Ecotoxicology, Toxicology of Chemicals Intelligent testing strategies in ecotoxicology: mode of action approach for specifically acting chemicals. Technical Report No. 102 2007, ECETOC, Brussels (BE).
18. [EMEA/CHMP] European Medicines Agency/Committee for Medicinal Products for Human Use Guideline on the environmental risk assessment of medicinal products for human use. EMEA/CHMP/SWP/4447/00 2006, EMEA, London, UK.
19. Ericson H., Thorsén G., Kumblad L. Physiological effects of diclofenac, ibuprofen and propranolol on Baltic Sea blue mussels. Aquatic Toxicology 2010, 99:223-231.
20. Fabbri E., Capuzzo A. Cyclic AMP signaling in bivalve molluscs: an overview. Journal of Experimental Zoology Part A 2010, 313:179-200.
21. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquatic Toxicology 2006, 76:122-159.
22. Fong P.P., Philbert C.M., Roberts B.J. Putative serotonin reuptake inhibitor-induced spawning and parturition in freshwater bivalves is inhibited by mammalian 5-HT2 receptor antagonists. Journal of Experimental Zoology Part A Comparative Experimental Biology 2003, 298:67-72.
23. Franzellitti S., Buratti S., Donnini F., Fabbri F. Exposure of mussels to a polluted environment: insights into the stress syndrome development. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2010, 152:24-33.
24. Franzellitti S., Buratti S., Valbonesi P., Capuzzo A., Fabbri E. The β-blocker propranolol affects cAMP-dependent signaling and induces the stress response in Mediterranean mussels, Mytilus galloprovincialis. Aquatic Toxicology 2011, 101:299-308.
25. Franzellitti S., Capuzzo A., Viarengo A., Fabbri E. Interactive effects of nickel and chlorpyrifos on Mediterranean mussel cAMP-mediated cell signaling and MXR-related gene expressions. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 2011, 154:377-382.
26. Franzellitti S., Fabbri E. Cyclic-AMP mediated regulation of ABCB mRNA expression in mussel haemocytes. PLoS ONE 2013, 8:e61634.
27. Gagnè F., Blaise C., Andrè C., Gagnon C., Salazar M. Neuroendocrine disruption and health effects in Elliptio complanata mussels exposed to aeration lagoons for wastewater treatment. Chemosphere 2007, 68:731-743.
28. Gunnarsson L., Jauhiainen A., Kristiansson E., Nerman O., Larsson D.G.J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environmental Science & Technology 2008, 42:5807-5813.
29. Gros M., Petrović M., Barceló D. Development of a multi-residue analytical methodology based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) for screening and trace level determination of pharmaceuticals in surface and wastewaters. Talanta 2006, 70:678-690.
30. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behavioural Brain Research 2008, 195:198-213.
31. Heberer T. Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: a review of recent research data. Toxicology Letter 2002, 131:5-17.
32. Hiemke C., Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & Therapeutics 2000, 85:11-28.
33. Kim J.W., Ishibashi H., Yamauchi R., Ichikawa N., Takao Y., Hirano M., Koga M., Arizono K. Acute toxicity of pharmaceutical and personal care products on freshwater crustacean (Thamnocephalus platyurus) and fish (Oryzias latipes). Journal of Toxicological Sciences 2009, 34:227-232.
34. Kim J.W., Jang H.S., Kim J.G., Ishibashi H., Hirano M., Nasu K., Ichikawa N., Takao Y., Shinohara R., Arizono K. Occurrence of pharmaceutical and personal care products in surface water from Mankyung River, South Korea. Journal of Health Science 2009, 55:249-258.
35. Kolpin D.W., Furlong E.T., Meyer M.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environmental Science Technology 2002, 36:1202-1211.
36. Kreke N., Dietrich D.R. Physiological endpoints for potential SSRI interactions in fish. Critical Reviews in Toxicology 2008, 37:215-247.
37. Larsson D.G., de Pedro C., Paxeus N. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. Journal of Hazardous Materials 2007, 148:751-755.
38. Liu Q.T., Williams T.D., Cumming R.I., Holm G., Hetheridge M.J., Murray-Smith R. Comparative aquatic toxicity of propranolol and its photodegraded mixtures: algae and rotifer screening. Environmental Toxicology and Chemistry 2009, 28:2622-2631.
39. Livak K.J., Schmittgen T.D. Analyzing real-time PCR data by the comparative CT method. Nature Protocols 2008, 3:1101-1108.
40. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
41. Martin-Diaz M.L., Franzellitti S., Buratti S., Valbonesi P., Capuzzo A., Fabbri E. Effects of environmental concentrations of the antiepileptic drug carbamazepine on biomarkers and cAMP-mediated cell signaling in the mussel Mytilus galloprovincialis. Aquatic Toxicology 2009, 94:177-185.
42. Metcalfe C.D., Miao X.-S., Koenig B.G., Struger J. Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environmental Toxicology and Chemistry 2003, 22:2881-2889.
43. Nakamura Y., Yamamoto H., Sekizawa J., Kondo T., Hirai N., Tatarazako N. The effects of pH on fluoxetine in Japanese medaka (Oryzias latipes): acute toxicity in fish larvae and bioaccumulation in juvenile fish. Chemosphere 2008, 70:865-873.
44. Oakes K.D., Coors A., Escher B.I., Fenner K., Garric J., Gust M., Knacker T., Küster A., Kussatz C., Metcalfe C.D., Monteiro S., Moon T.W., Mennigen J.A., Parrott J., Péry A.R., Ramil M., Roennefahrt I., Tarazona J.V., Sánchez-Argüello P., Ternes T.A., Trudeau V.L., Boucard T., Van Der Kraak G.J., Servos M.R. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: case study using the European risk assessment framework. Integrated Environmental Assessment and Management 2010, 6:524-539.
45. Owen S.F., Huggett D.B., Hutchinson T.H., Hetheridge M.J., Kinter L.B., Ericson J.F., Sumpter J.P. Uptake of propranolol, a cardiovascular pharmaceutical, from water into fish plasma and its effects on growth and organ biometry. Aquatic Toxicology 2009, 93:217-224.
46. Paetzold S.S., Ross N.W., Richards R.C., Jones M., Hellou J., Bard S.M. Up-regulation of hepatic ABCC2, ABCG2, CYP1A1 and GST in multixenobiotic-resistant killifish (Fundulus heteroclitus) from the Sydney Tar Ponds, Nova Scotia, Canada. Marine Environmental Research 2009, 68:37-47.
47. Santos L.H., Araújo A.N., Fachini A., Pena A., Delerue-Matos C., Montenegro M.C. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. Journal of Hazardous Materials 2010, 175:45-95.
48. Schmitt H., Boucard T., Garric J., Jensen J., Parrott J., Péry A., Römbke J., Straub J.-O., Hutchinson T.H., Sánchez-Argüello P., Wennmalm A., Duis K. Recommendations on the environmental risk assessment of pharmaceuticals: effect characterization. Integrated Environmental Assessment and Management 2010, 6:S588-S602.
49. SRC, 2007. SRC PhysProp Database, Syracuse Research Corporation. 07/2007. Available from: http://www.syrres.com/esc/physdemo.htm.
50. Thomas K.V., Hilton M.J. The occurrence of selected human pharmaceutical compounds in UK estuaries. Marine Pollution Bulletin 2004, 49:436-444.
51. Tierney A.J. Structure and function of invertebrate 5-HT receptors: a review. Comparative Biochemistry and Physiology - Part A 2001, 128:791-804.
52. Tinajero J.C., Fabbri A., Dufau M.L. Serotonergic inhibition of rat Leydig cell function by propranolol. Endocrinology 1993, 133:257-264.
53. Vanderford B.J., Snyder S.A. Analysis of pharmaceuticals in water by isotope dilution liquid chromatography/tandem mass spectrometry. Environmental Science & Technology 2006, 40:7312-7320.
54. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 2002, 3:0034.1.
55. Vasskog T., Anderssen T., Pedersen-Bjergaard S., Kallenborn R., Jensen E. Occurrence of selective serotonin reuptake inhibitors in sewage and receiving waters at Spitsbergen and in Norway. Journal of Chromatography A 2008, 1185:194-205.
56. [VICH] International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products Environmental impact assessment (EIAs) for veterinary medicinal products (VMPs) - Phase I. VICH Guideline 6 (Ecotoxicity Phase I). CVMP/VICH/592/98-FINAL 2000, VICH, London, UK.
57. [VICH] International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products Environmental impact assessment (EIAs) for veterinary medicinal products (VMPs) - Phase II Guidance. VICH Guideline 38 (Ecotoxicity Phase II). CVMP/VICH/790/03-FINAL 2005, VICH, London, UK.
58. Weir M.R. Beta-blockers in the treatment of hypertension: are there clinically relevant differences?. Postgraduate Medicine 2009, 121:90-98.
59. Wille K., Claessens M., Rappé K., Monteyne E., Janssen C.R., De Brabander H.F., Vanhaecke L. Rapid quantification of pharmaceuticals and pesticides in passive samplers using ultra high performance liquid chromatography coupled to high resolution mass spectrometry. Journal of Chromatography A 2011, 1218:9162-9173.
60. Wille K., Noppe H., Verheyden K., Vanden Bussche J., De Wulf E., Van Caeter P., Janssen C.R., De Brabander H.F., Vanhaecke L. Validation and application of an LC-MS/MS method for the simultaneous quantification of 13 pharmaceuticals in seawater. Analytical and Bioanalytical Chemistry 2010, 397:1797-1808.